Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

4.285 -0.525 (-10.91%)
Streaming Delayed Price Updated: 12:07 PM EDT, Apr 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,059,154
Open 4.590
Bid (Size) 4.280 (28)
Ask (Size) 4.290 (41)
Prev. Close 4.810
Today's Range 4.060 - 4.740
52wk Range 4.780 - 12.36
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March
Via The Motley Fool
Topics Bankruptcy Economy World Trade
Exposures Economy Financial Legal
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire

Performance

YTD
-40.6%
-40.6%
1 Month
-33.8%
-33.8%
3 Month
-40.6%
-40.6%
6 Month
-29.3%
-29.3%
1 Year
-52.0%
-52.0%

More News

Read More
Why Biotech Stocks Like Recursion Pharmaceuticals, CRISPR Therapeutics, and Summit Therapeutics Plunged Today
Via The Motley Fool
Topics Government World Trade
Exposures COVID-19 Political Product Safety
Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Why Recursion Pharmaceuticals Stock Is Sinking Today
Via The Motley Fool
Nvidia Has 81% of Its $304 Million Stock Portfolio Invested in 3 Groundbreaking AI Stocks
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Jim Cramer: Fiserv Is 'One Of The Greatest Fintechs,' Calls This Tech Company A Meme Stock
Via Benzinga
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip
Via Benzinga
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun
From Recursion Pharmaceuticals
Via GlobeNewswire
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today
Via The Motley Fool
This Biotech Stock Could Be the Best Investment of the Decade
Via The Motley Fool
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?
Via The Motley Fool
Recursion Pharmaceuticals' Update Could Shed Light On Pipeline, Cost-Saving Plans, Analyst Says
Via Benzinga
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip
Via Stocktwits
Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Earnings Scheduled For February 28, 2025
Via Benzinga
Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th
From Recursion Pharmaceuticals
Via GlobeNewswire
Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite?
Via MarketBeat
Topics Artificial Intelligence Regulatory Compliance
Exposures Artificial Intelligence Legal Regulatory
SoundHound and Serve Robotics Are Dropping Like a Rock -- Why Nvidia Was the Catalyst
Via The Motley Fool
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
25 Top AI Stocks That Could Boost Your Portfolio
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City
From Recursion Pharmaceuticals
Via GlobeNewswire
Altitude Lab Startups Raise $154M in Capital
From Recursion Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Recursion Pharmaceuticals, Inc. - Class A Common Stock publicly traded?
Yes, Recursion Pharmaceuticals, Inc. - Class A Common Stock is publicly traded.
What exchange does Recursion Pharmaceuticals, Inc. - Class A Common Stock trade on?
Recursion Pharmaceuticals, Inc. - Class A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The ticker symbol for Recursion Pharmaceuticals, Inc. - Class A Common Stock is RXRX on the Nasdaq Stock Market
What is the current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock?
The current price of Recursion Pharmaceuticals, Inc. - Class A Common Stock is 4.285
When was Recursion Pharmaceuticals, Inc. - Class A Common Stock last traded?
The last trade of Recursion Pharmaceuticals, Inc. - Class A Common Stock was at 04/04/25 12:07 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.